Pembrolizumab for high-risk thyroid cancer that cannot be fully removed
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This study tests pembrolizumab (an immune therapy) in people with high-risk thyroid cancer that is hard to treat with surgery alone. It looks at whether this drug can reduce persistent or recurrent cancer after your planned treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older, with thyroid cancer confirmed by biopsy or surgery (histology), and the cancer is a type that can be treated as differentiated thyroid cancer, poorly differentiated cancer, or Hürthle cell cancer.
- Your cancer is high-risk (for example: large tumor, spread outside the thyroid, lymph node involvement with spread beyond nodes, BRAF V600E mutation in certain cases, expected incomplete removal, or disease already spread to distant sites).
- Your cancer can be measured on scans (your team can track it using RECIST 1.1).
- Your general health is good (ECOG 0–1) and your heart, liver, kidneys, and blood counts are adequate for study treatment.
- You must not have had prior immune checkpoint therapy (anti–PD-1/PD-L1/PD-L2) or similar immune T-cell–targeting drugs.
- You must not have active uncontrolled problems that block immune therapy, such as untreated infection, ongoing steroid-level immunosuppression, active autoimmune disease needing immune treatment, or current lung inflammation (pneumonitis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies pembrolizumab, an immunotherapy medicine, in people with thymoma or thymic cancer that cannot be removed with surgery. It aims to see how well the treatment works and how safe it is, including whether your immune system can help control the cancer.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
This trial tests whether a drug called pembrolizumab (Keytruda) can help people with advanced throat cancer avoid removal of the voice box. You may be eligible if you have a specific type of larynx or hypopharynx cancer that hasn't been treated with radiation or immunotherapy before.
This trial tests a combination of two drugs, sinibolimab (an immunotherapy) and lenvatinib (a targeted therapy), given before surgery to shrink locally advanced thyroid cancer that cannot be fully removed. The goal is to make the tumor removable and improve outcomes.
Hear when a new Differentiated Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.